It really is going to depend on dose. If an Ac225bisPSMA construct can get more of the Ac225 to the tumour then you can reduce the dose and avoid causing the kidney damage that comes with renal excretion.
I don’t think CU6 is running a Ac225 program because they really believe it is needed, but it is a program designed to appeal a big player that does believe in Ac225. What I want to hear more about is the click chemistry technology they bought a little while back. That has the potential to really revolutionise radiotheranostics and we have heard nothing much about it since the purchase,
CU6 - Media and Industry News, page-521
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.15 |
Change
0.160(2.29%) |
Mkt cap ! $2.289B | |||
| Open | High | Low | Value | Volume |
| $7.05 | $7.19 | $6.91 | $3.595M | 509.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $7.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.16 | 3007 | 3 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |